- Research Article
1
- 10.1164/ajrccm.2025.211.abstracts.a5979
Pulmonary Nodules and Granulomatous Lung Disease in a Case of Rheumatoid Arthritis: A Paradoxical Occurrence With TNF-α Inhibitor Use
- May 01, 2025
- American Journal of Respiratory and Critical Care Medicine
- D Bilagi + 3 more +3
Abstract Introduction: TNF-α inhibitors, now widely used in clinical practice, have revolutionized treatment of Rheumatoid arthritis(RA) in slowing disease progression and improving quality of life. Long term use of this group of medications is unraveling paradoxical but rare adverse effects of granulomatous lung disease which can lead to discontinuation of treatment and exploring alternative therapies. Case Description: A 47 year-old female with RA, biopsy proven follicular bronchiolitis, cough variant asthma, diabetes, hepatitis B, and hypothyroidism presented with worsening cough and shortness of breath for two months. She was on Etanercept for 21 years. Her physical exam was unremarkable. Fungal infectious work-up was negative and she responded poorly to short courses of steroids and antibiotics. A CT chest revealed multiple bilateral noncalcified pulmonary nodules largest measuring 16 mm and 14 mm in right and left upper lobes. Also noted was significant mediastinal and hilar lymphadenopathy with a subcarinal lymph node of 4.3 cm. This prompted an endobronchial ultrasound guided transbronchial needle aspiration of lymph nodes to rule out malignancy. Pathology revealed granulomatous inflammation. Tissue samples were negative for AFB/fungal stains. Lavage fluid cultures were negative for infection. This confirmed diagnosis of TNF-α inhibitor induced granulomatous lung disease. Etanercept was discontinued and the patient was treated with high dose steroids and PJP prophylaxis coverage. Patient reported symptomatic improvement on follow-up visit. A repeat CT chest in 4 months showed resolution of lymphadenopathy and lung nodules. Discussion: Several cases of sarcoid-like granulomatosis have been reported with TNF-α inhibitors use in RA and other spondyloarthritides causing reticulonodular lung involvement and mediastinal lymphadenopathy. This resolves after drug discontinuation with or without steroid use. A marked variability is noted in delay between drug onset and identification of granulomatosis which makes diagnosis challenging. The exact mechanism and long term prognostication of this complication is not well studied, and is thought to be from cytokine dysregulation. Our case presented after 21 years of drug use and responded to etanercept discontinuation and steroids. Patient was later switched to sulfasalazine for her joint symptoms. Lymphadenopathy and pulmonary nodules were resolved on follow up imaging. Although rare in occurrence, one must be vigilant of this potential complication. We recommend biopsy to rule out other conditions like rheumatoid nodules, infections or malignancy before arriving at a diagnosis.
Read more